Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice (Q57150920)

2

0 references

Eric Schryver

3

0 references

Nisreen S Akel

4

0 references

R Shane Shelton

5

0 references

Jessica Webber

6

0 references

Francis L Swain

7

0 references

Jami Schmidt

8

0 references

Larry J Suva

9

0 references

Dana Gaddy

Aneuploidy and skeletal health.

10

0 references

language of work or name

English

0 references

publication date

January 2018

0 references

published in

JBMR Plus

0 references

volume

2

0 references

issue

1

0 references

page(s)

47-54

0 references

cites work

1 reference

Maternal age specific risk rate estimates for Down syndrome among live births in whites and other races from Ohio and metropolitan Atlanta, 1970-1989

21 January 2018

1 reference

Endocrine and musculoskeletal abnormalities in patients with Down syndrome

21 January 2018

1 reference

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a

21 January 2018

1 reference

Low bone turnover and low bone density in a cohort of adults with Down syndrome

21 January 2018

1 reference

Bone mineral density in adults with Down's syndrome

21 January 2018

1 reference

Bone mass, gonadal function and biochemical assessment in young men with trisomy 21.

21 January 2018

1 reference

Bone mineral mass in males and females with and without Down syndrome.

21 January 2018

1 reference

Bone mass in male and female children and adolescents with Down syndrome.

21 January 2018

1 reference

Gonadal function in young women with Down syndrome.

21 January 2018

1 reference

Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

21 January 2018

1 reference

Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives

21 January 2018

1 reference

Of mice and men: divergent risks of teriparatide-induced osteosarcoma

21 January 2018

1 reference

Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading

21 January 2018

1 reference

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms

21 January 2018

1 reference

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

21 January 2018

1 reference

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

Physiological role of mGSTA4-4, a glutathione S-transferase metabolizing 4-hydroxynonenal: generation and analysis of mGsta4 null mouse

21 January 2018

1 reference

Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease

21 January 2018

1 reference

Guidelines for assessment of bone microstructure in rodents using micro-computed tomography

21 January 2018

1 reference

Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

21 January 2018

1 reference

Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures

21 January 2018

1 reference

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study

21 January 2018

1 reference

Prevalence of fractures in women with intellectual disabilities: a chart review

21 January 2018

1 reference

BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.

21 January 2018

1 reference

Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis

21 January 2018

1 reference

Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta

21 January 2018

1 reference

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

21 January 2018

1 reference

Characteristics of adults with down syndrome: prevalence of age-related conditions

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6124205

Health care concerns and guidelines for adults with Down syndrome

2 November 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6124205

Inhibin A is an endocrine stimulator of bone mass and strength

2 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30283889

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bone mass in young adults with Down syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30283889